1. Introduction {#sec1-jcm-08-01903}
===============

Colon cancer is the second leading cause of cancer-related death worldwide, with an incidence of 9.2% \[[@B1-jcm-08-01903]\]. Although curative surgical resection of primary lesions and post-operative adjuvant treatment contribute to the prevention of early recurrence in patients with high-risk stage II and III colon cancer, the recurrence rate after curative surgery remains at 20%--30% \[[@B2-jcm-08-01903]\]. To prolong disease-free survival (DFS) after curative surgery and avoid unnecessary over-treatment of patients, more accurate prognostic tools are required. However, a few clinical prognostic factors, such as the presence of obstructive symptoms, number of retrieved regional lymph nodes, pathologic tumor and nodal stage, and features associated with micrometastatic potential including vascular, lymphatic, and perineural invasion, have been used to select patients that may benefit from adjuvant therapies \[[@B3-jcm-08-01903]\]. Although other molecular signatures, such as microsatellite status, BRAF (v-Raf murine sarcoma viral oncogene homolog B) and KRAS (V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) mutations, molecular signatures, and immune infiltration, have been suggested as potential prognosticators, more sophisticated prognostic biomarkers need to be identified \[[@B1-jcm-08-01903],[@B3-jcm-08-01903]\].

To identify accurate and definitive molecular biomarkers for human malignancies, we previously developed a neural network-based model, Wx, which is optimized to select gene sets based on the discriminative index between combination pairs of K class \[[@B4-jcm-08-01903]\]. In our previous report, we applied our Wx model to a pan-cancer cohort from The Cancer Genome Atlas (TCGA) RNA-Seq dataset, consisting of 12 different types of cancer and normal samples, and obtained 14 genes distinguishing cancer tissues from normal tissues with high accuracy. Tissue elongation factor 1 alpha 1 (*EEF1A1*) was one of the 14 biomarker genes extracted using the Wx model. Interestingly, it was also identified by Martinez-Ledesma et al. using the same discriminative concept to compare colon adenocarcinoma to normal tissues \[[@B5-jcm-08-01903]\].

EEF1A1 is a ubiquitous protein that functions in peptide elongation during mRNA translation and is the second-most abundant protein after actin in eukaryotic proteomes \[[@B6-jcm-08-01903],[@B7-jcm-08-01903]\]. As a translational factor, EEF1A delivers the aminoacylated-tRNA to the ribosome, as a ternary complex comprising EEF1A--GTP (Guanosine-5'-triphosphate)--aminoacylated-tRNA, to decode mRNA. There are two isoforms of *EEF1A*, namely *EEF1A1* and *EEF1A2*, which were mapped to chromosomes 6q14 and 2q13.3, respectively \[[@B8-jcm-08-01903]\]. *EEF1A1* and *EEF1A2* share more than 95% DNA and protein identity \[[@B9-jcm-08-01903]\]. EEF1A1 is expressed in most cells, whereas EEF1A2 is present only in the brain, heart, and skeletal muscle \[[@B10-jcm-08-01903]\]. Although the functional significance of their tissue-specific expression patterns is unknown, they are thought to have the same enzymatic function in protein translation. Several studies have revealed that EEF1A is not only a translation factor but also involved in many non-canonical functions including oncogenesis, protein degradation, pro-apoptotic or anti-apoptotic activity, and cytoskeleton modulation \[[@B10-jcm-08-01903],[@B11-jcm-08-01903],[@B12-jcm-08-01903],[@B13-jcm-08-01903]\]. Notably, many studies have shown that *EEF1A* is a prognostic factor for several solid tumors such as ovary \[[@B11-jcm-08-01903],[@B14-jcm-08-01903]\], breast \[[@B15-jcm-08-01903],[@B16-jcm-08-01903],[@B17-jcm-08-01903]\], lung \[[@B18-jcm-08-01903]\], pancreas \[[@B19-jcm-08-01903],[@B20-jcm-08-01903]\], stomach \[[@B21-jcm-08-01903],[@B22-jcm-08-01903]\], prostate \[[@B23-jcm-08-01903]\], and liver cancers \[[@B24-jcm-08-01903],[@B25-jcm-08-01903]\]. Based on the previous results from the Wx neural network-based feature selection algorithm and those reporting the role of EEF1A1 in human solid cancer, we hypothesized that EEF1A1 is related to the prognosis of patients with colon adenocarcinoma. In this study, we investigated the expression of EEF1A in tissues from patients with stage II and III colon cancer and analyzed its association with patient prognosis.

2. Methods {#sec2-jcm-08-01903}
==========

2.1. Identification of Prognostic Biomarker Genes Using the Wx Algorithm with TCGA Database {#sec2dot1-jcm-08-01903}
-------------------------------------------------------------------------------------------

Genes distinguishing cancer from normal samples were identified by applying the Wx algorithm to a pan-cancer cohort containing 6210 samples with 12 different types of cancer, using mRNA-Seq data from TCGA. In this study, we re-analyzed the mRNA-Seq data of 327 colon adenocarcinomas (287 cancer and 40 normal samples) to identify biomarker candidate genes using the Wx algorithm. The Wx algorithm ranks genes based on the discriminative index score, which reflects the classification power of distinction between groups (e.g., cancer vs. normal). The detailed method has been described previously \[[@B4-jcm-08-01903]\].

2.2. Patients and Tissue Samples {#sec2dot2-jcm-08-01903}
--------------------------------

Medical records of patients with colon cancer who have undergone curative surgery at Incheon St. Mary's hospital between 2010 and 2013 were reviewed. Their tissue microarrays (TMAs) for immunohistochemistry were obtained. If available, fresh-frozen tumor tissues and paired normal adjacent tissues from patients were used for RNA extraction. Demographic and clinicopathological data for these patients were reviewed retrospectively from the medical records. Variable factors including age, sex, sidedness of colon cancer, pathologic staging, histology, and lymphatic, venous, and perineural invasion were analyzed, and tumors were staged according to the pathological tumor/node/metastasis (pTNM) classification (8th edition) of the Union for International Cancer Control. The study was approved by the Institutional Review Board of Incheon St. Mary's hospital, the Catholic University of Korea (OC15TISI0050). Informed consent was waived considering the retrospective study design.

2.3. Quantitative Reverse Transcription PCR (qRT-PCR) {#sec2dot3-jcm-08-01903}
-----------------------------------------------------

Total RNA was isolated from tumors and adjacent normal tissues of patients with colon cancer using the WelPrep^TM^ Total RNA Isolation Reagent (Welgene, Daegu, Korea) and gentleMACS Dissociator (Miltenyi Biotec, Bergisch Gladbach, Germany), according to the manufacturer's protocols. To analyze mRNA levels, qRT-PCR assays were performed using a BioFACT^TM^ A-Star Real-time PCR Kit including SFCgreen® I (BioFACT, Daejeon, Korea) after reverse transcription with ELPIS RT Prime Kit (Elpis-Biotech, Daejeon, Korea). mRNA levels were normalized to those of ribosomal protein L32 (*RPL32*).

2.4. Tissue Microarray Construction and Immunohistochemistry {#sec2dot4-jcm-08-01903}
------------------------------------------------------------

Formalin-fixed paraffin-embedded colon cancer samples from patients who underwent surgery were included in a TMA after careful review by two experienced pathologists. TMAs were prepared with a tissue array and were composed of 69 cores per TMA, with a core diameter of 2 mm. The cores were derived from separate sources and treated as individual cases, and not as duplicates from a single source. Cases that presented as colon cancer had sufficient material for two cores, whereas normal tissues could be used to generate one core. A set comprising 14 slides was stained by immunohistochemistry. The antibodies used for the study included a mouse monoclonal antibody against EEF1A1 (sc-21758) from Santa Cruz Biotechnology, Inc. (Dallas, TX, USA), which was used according to the manufacturer's instructions at a dilution of 1:100 after optimization. Immunohistochemical staining was carried out with the Ventana BenchMark ULTRA (Tucson, AZ, USA) using the ultraView Universal DAB detection kit. This included standard de-paraffinization, blocking of endogenous peroxidase and biotin, incubation with primary and secondary antibodies, and development with DAB (di-aminobenzidine). The slides were counterstained with hematoxylin and eosin (H&E).

2.5. Evaluation of Immunohistochemical Staining of EEF1A1 {#sec2dot5-jcm-08-01903}
---------------------------------------------------------

Immunohistochemical staining for EEF1A1 revealed its cytoplasmic expression in most tumor cells. Staining intensity was graded from 0 to 3 (0 = no expression, 1 = weak, 2 = moderate, and 3 = strong). The extent was graded from 0 to 2 (0 = 0%, 1 = 1%--50%, 2 = 51%--100% of cells) ([Figure 1](#jcm-08-01903-f001){ref-type="fig"}). The intensity and extent scores were added to obtain a composite score. Patients with composite scores of 0--2 were classified into the low-EEF1A1 expression group and those with scores of 3--6 were included in the high-expression group. The results were analyzed by two pathologists who were blinded to the clinical data.

2.6. Statistical Analysis {#sec2dot6-jcm-08-01903}
-------------------------

Categorical values were presented as means and percentages, and non-categorical values were presented as median values and ranges. The Chi-squared test and one-way analysis of variance were performed to compare differences among means and medians, respectively. The Kaplan--Meier method was used to calculate survival rates. DFS was defined as the period from the date of curative operation of colon cancer to the date of recurrence based on medical records. Overall survival (OS) was defined as the period from the date of curative operation of colon cancer to the date of death due to any cause. Right colon cancer was defined as cancer originating from the ascending colon to the splenic flexure and left colon cancer was defined as originating from the descending colon to the sigmoid colon. A *p*-value \< 0.05 was considered to indicate statistical significance. Differences in survival rates across each patient group were examined by the log-rank test. A Cox proportional-hazards model was used for univariate and multivariate analyses. All analyses were performed with SPSS for windows (version 25.0, SPSS, Inc., Chicago, IL, USA).

3. Results {#sec3-jcm-08-01903}
==========

3.1. Baseline Characteristics of the Study Population {#sec3dot1-jcm-08-01903}
-----------------------------------------------------

A total of 281 patients with colon cancer who underwent curative resection as the primary treatment were retrospectively analyzed. Of them, 132 patients (47.0%) had stage II disease, whereas the remaining 149 (53.0%) had stage III lesions. Among patients with stage II, 89 (67.4%) were administered post-operative adjuvant treatment. The median pre-operative carcinoembryonic antigen (CEA) value was 3.34 ng/mL (range: 0.08--1926.6 ng/mL). The *KRAS* status was identified in only 143 patients and *KRAS* mutations were observed in 52 (36.4%) tumor tissues. The detailed demographic features of these patients are summarized in [Table 1](#jcm-08-01903-t001){ref-type="table"}.

3.2. mRNA Expression of EEF1A1 in Human Colon Cancer Tissues Compared to That in Normal Adjacent Tissues {#sec3dot2-jcm-08-01903}
--------------------------------------------------------------------------------------------------------

Of the total study population, *EEF1A1* mRNA expression levels were investigated in 15 patients from whom fresh tumor and adjacent normal tissue could be harvested. *EEF1A1* mRNA levels were significantly reduced in the tumor tissues compared to those in the normal adjacent tissue ([Figure 2](#jcm-08-01903-f002){ref-type="fig"}).

3.3. Correlation between EEF1A1 Expression and Clinicopathological Characteristics {#sec3dot3-jcm-08-01903}
----------------------------------------------------------------------------------

EEF1A1 immunostaining was typically negative or very weakly positive in the perinuclear cytoplasmic area of the normal colonic mucosa. In the tissue with positive EEF1A1 immunostaining, diffuse cytoplasmic staining was observed in tumor cells. The intensity of EEF1A1 was as follows: intensity 0:19 patients (6.8%), 1:86 (30.6%), 2:139 (49.5%), and 3:37 (13.2%). According to composite scores, 42 (14.9%) patients were classified as having low EEF1A1 expression, whereas 239 patients (85.1%) were classified as having high expression ([Table S1](#app1-jcm-08-01903){ref-type="app"}). Stage, age, sex, harvested lymph node during surgery, and the proportion of patients administered post-operative adjuvant treatment did not differ between patients with low and high expression. Intestinal obstruction or perforation, due to primary colon cancer, was more frequently observed in patients with low EEF1A1 expression than in those with high expression. Patients with low EEF1A1 expression tended to have a larger proportion of right-sided tumors than those with high expression, although this result was not significant. KRAS mutations were not associated with EEF1A1 expression (*p* = 0.399). Other patient clinicopathological characteristics, according to EEF1A1 expression, are listed in [Table 1](#jcm-08-01903-t001){ref-type="table"}.

3.4. Survival Outcomes According to EEF1A1 Expression {#sec3dot4-jcm-08-01903}
-----------------------------------------------------

The median follow-up period was 59.9 months (range 1.7--110.0 months). Considering all patients, the five-year OS in the high-EEF1A1 group was 87.7%, whereas it was 65.6% in the low-EEF1A1 expression group (*p* = 0.002, hazard ratio (HR) = 2.47, 95% confidence interval (CI) = 1.38--4.44) ([Figure 3](#jcm-08-01903-f003){ref-type="fig"}a). The five-year DFS of patients with high EEF1A1 expression was 82.5%, which was longer than the rate of 55.4% observed for patients with low EEF1A1 expression (*p* \< 0.001, HR = 2.94, 95% CI = 1.72--5.04) ([Figure 3](#jcm-08-01903-f003){ref-type="fig"}b).

For stage II cancer, the 5-year OS of patients with high EEF1A1 expression tended to be longer than that of patients with low EEF1A1 expression (89.0% vs. 71.1%, *p* = 0.051, HR = 2.68, 95% CI = 0.96--7.43). The 5-year DFS of patients with high EEF1A1 was 88.0%, compared to 75.4% for those with low EEF1A1 (*p* = 0.134, HR = 2.30, 95% = CI 0.75--7.07). Among patients with stage II disease who were not administered post-operative adjuvant treatment, those with high EEF1A1 expression had a longer OS (5-year OS rate, 87.7%) than those with low EEF1A1 levels (57.1%) (*p* = 0.026). This survival difference according to EEF1A1 expression was not observed for patients administered adjuvant treatment after stage II disease (*p* = 0.985). For stage III cancer, the 5-year OS was 88.1% for patients with high EEF1A1 expression and 62.6% for those with low EEF1A1 (*p* = 0.030, HR = 2.22, 95% CI = 1.06--4.50) ([Figure 4](#jcm-08-01903-f004){ref-type="fig"}a). Among patients with stage III disease, the 5-year DFS for patients in the high-EEF1A1 group was 78.7%, compared to 50.0% for those with low EEF1A1 (*p* = 0.001, HR = 2.72, 95% = CI 1.45--6. 09) ([Figure 4](#jcm-08-01903-f004){ref-type="fig"}b).

3.5. Factors Associated with Survival in Patients with Stages II and III Colon Cancer {#sec3dot5-jcm-08-01903}
-------------------------------------------------------------------------------------

Univariate Cox regression analysis indicated that age, pre-operative CEA levels, adjuvant treatment, total number of metastatic lymph nodes, and EEF1A1 expression levels were significant prognostic factors for death. Based on multivariate analysis, the expression of EEF1A1 retained its independence as a prognostic factor associated with death (HR = 3.01, 95% CI = 1.636--5.543, *p* \< 0.001) ([Table 2](#jcm-08-01903-t002){ref-type="table"}). EEF1A1 expression was also an independent prognostic factor for recurrence based on multivariate analysis (HR = 2.54, 95% CI = 1.459--4.434, *p*-value \< 0.001). Other significant prognostic markers for DFS included pre-operative CEA level and TNM stage ([Table 3](#jcm-08-01903-t003){ref-type="table"}).

4. Discussion {#sec4-jcm-08-01903}
=============

*EEF1A1* was a biomarker used to distinguish between cancer and normal tissue in our previous study, using a neural network-based feature selection algorithm. In the present study, we investigated EEF1A1 expression and its prognostic significance for patients with stage II and III colon cancer who underwent curative resection. The results revealed that *EEF1A1* mRNA was decreased in tumor tissue compared to that in normal tissue. Patients with low expression of EEF1A1 showed poorer survival outcomes in terms of both DFS and OS compared to those with higher expression. The expression level of EEF1A1 was found to be an independent prognostic factor for survival outcomes. Among stage II patients not administered adjuvant treatment, a poorer OS outcome was observed for those with low EEF1A1 expression than for those with high EEF1A1 expression. Among patients with stage III colon cancer, those with low EEF1A1 expression had a shorter OS than those with high EEF1A1 expression. We determined the prognostic effect of EEF1A1 on human colon cancer. To the best of our knowledge, this is the first study to investigate the prognostic value of EEF1A1 expression in human colon cancer.

The physiological role of EEF1A1 in eukaryotic protein synthesis involves recruiting amino-acylated tRNA to the ribosome during the elongation phase of translation. It also plays various non-canonical roles including cytoskeleton modulation, protein degradation, apoptosis, and oncogenesis \[[@B12-jcm-08-01903],[@B13-jcm-08-01903]\]. Particularly, EEF1A1 has been reported to be a pro-apoptotic protein in previous studies. Ruest et al. reported that myotube death is accelerated by the induction of the homologous gene \[[@B26-jcm-08-01903]\], *EEF1A-1/EF-1α.* Borradaile et al. demonstrated that induction of *EEF1A1* is involved in lipotoxic cell death secondary to oxidative stress \[[@B27-jcm-08-01903]\]. Bosutti et al. compared the mRNA levels of *EEF1A1*, *EEF1A2*, and other pro-apoptotic genes (*p66* and *c-MYC*) in skeletal muscles between severely traumatized patients and healthy volunteers \[[@B28-jcm-08-01903]\]; the results showed upregulation of muscle *EEF1A1* and *p66* in the traumatized patient group, which was significantly related to the proteolysis rate. Thus, pro-apoptotic function is a possible mechanism underlying the protective effect of EEF1A1 against tumor development or progression. However, the tumor suppressive role of EEF1A1 in colon adenocarcinoma remains unclear. EEF1A1 expression has been determined to be independent of *KRAS* mutations in our study, suggesting that the expression of EEF1A1 is unlikely to involve *KRAS*-related colon adenocarcinoma. However, one study suggested that posttranslational changes in EEF1A1 might affect the KRAS pathway. Liu et al. suggested an association between EEF1A1 and *KRAS*-related tumorigenicity \[[@B29-jcm-08-01903]\], demonstrating that neoplastic cell growth induced by oncogenic KRAS signaling may be associated with methylation of *EEF1A1* at the mRNA or protein level. Additionally, the results of the current study revealed that EEF1A1 expression was associated with tumor location, and right-sided colon cancers tended to show lower expression of EEF1A1, although the correlation with tumor sidedness was not significant. The biological role of EEF1A1 in colon adenocarcinoma and its correlation with tumor sidedness will be evaluated in our next study.

Based on our results, high expression of EEF1A1 indicates a favorable survival prognosis for patients with colon cancer, and at the mRNA level, *EEF1A1* was found to be downregulated in tumor tissues compared to that in normal tissues. Lin et al. revealed that EEF1A1 protein is overexpressed in estrogen/progesterone receptor (ER/PR)-positive and lymph node-negative breast cancers, which have relatively favorable outcomes compared to ER/PR-negative and lymph node-positive cases \[[@B30-jcm-08-01903]\]. However, at the mRNA transcript level, low *EEF1A1* expression was an independent poor-prognostic factor with ER/PR-positive tumors; breast cancer-specific post-transcriptional regulatory events may be responsible for this discordance between the expression of *EEF1A1* mRNA and protein \[[@B30-jcm-08-01903]\]. Further, Hassan et al. investigated the mRNA transcript levels of *EEF1A* isoforms across different cancers such as lung, breast, gastric, brain, prostate, liver, and colon cancers using the Oncomine and TCGA databases \[[@B31-jcm-08-01903]\]. In colon cancer, *EEF1A1* mRNA expression levels were significantly low in patients with a high risk of recurrence compared to those in patients with a low risk, which was also consistent with our findings. Interestingly, based on our results, patients who did not undergo treatment for stage II colon cancer showed differences in OS according to EEF1A1 expression. In patients with stage II disease, EEF1A1 could serve as a potential biomarker for selecting candidates who may benefit from adjuvant treatment.

In contrast to our results, studies have reported that *EEF1A* downregulation leads to decreased expression of pAkt1, consequently inhibiting proliferation and invasion and promoting apoptosis in HCC (Hepato cellular carcinoma) cells \[[@B16-jcm-08-01903]\]. In stomach cancer, EEF1A1 has been reported to promote gastric cancer cell migration and invasion \[[@B21-jcm-08-01903]\]. Such contradictory reports regarding the role of EEF1A1 in tumorigenesis may be due to the fact that it plays fundamental roles in various cellular functions \[[@B12-jcm-08-01903]\]. Even in the same cancer, EEF1A1 may act in an opposing manner with respect to different subtypes or stages. For example, Hassan et al. suggested that higher *EEF1A1* expression \[[@B31-jcm-08-01903]\], which is otherwise a favorable biomarker for breast cancer, can be an indicator of poor OS, particularly in the basal subtype.

Our study has some limitations, such as its retrospective design. Further, the KRAS status was not verified in all populations. However, we analyzed a relatively homogeneous population, which compensates for these limitations. To the best of our knowledge, this is the first study to analyze the prognostic role of EEF1A1 in human colon cancer.

5. Conclusions {#sec5-jcm-08-01903}
==============

In conclusion, EEF1A1 may have a favorable prognostic effect on human colon adenocarcinoma, indicating that its loss can lead to poorer survival outcomes. Different expression levels of EEF1A protein in stages II and III of colon cancer may be independent prognostic markers of DFS and OS. Further studies are recommended to determine the mechanism underlying this correlation.

###### 

Click here for additional data file.
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![Immunohistochemical staining of elongation factor-1 alpha 1 (EEF1A1) in colon adenocarcinoma tissue. (**a**) Staining intensity 0; (**b**) staining intensity 1; (**c**) staining intensity 2; (**d**) staining intensity 3.](jcm-08-01903-g001){#jcm-08-01903-f001}

![Expression of EEF1A1 in colon cancer tissue and normal adjacent tissue.](jcm-08-01903-g002){#jcm-08-01903-f002}

![Kaplan--Meier survival curves according to EEF1A1 protein expression in all colon cancer patients. (**a**) High EEF1A1 expression was significantly associated with favorable overall survival (OS) and (**b**) disease-free survival (DFS).](jcm-08-01903-g003){#jcm-08-01903-f003}

![Kaplan--Meier survival curves according to EEF1A1 protein expression in stage III colon cancer patients. (**a**) High EEF1A1 expression was significantly associated with favorable overall survival (OS) and (**b**) disease-free survival (DFS).](jcm-08-01903-g004){#jcm-08-01903-f004}

jcm-08-01903-t001_Table 1

###### 

Baseline characteristics of colon cancer patients stratified based on EEF1A1 expression.

                                                     EEF1A1-Low (*n* = 42)   EEF1A1-High (*n* = 239)   *p*-Value
  -------------------------------------------------- ----------------------- ------------------------- -----------
  Age (years)                                                                                          
  \<65                                               22 (52.4%)              113 (47.3%)               0.616
  ≥65                                                20 (47.6%)              126 (52.7%)               
  Sex                                                                                                  
  Male                                               26 (61.9%)              129 (54.0%)               0.402
  Female                                             16 (38.1%)              110 (46.0%)               
  Body mass index (BMI) (kg/m^2)^                                                                      
  \<18.5                                             2 (4.8%)                17 (7.1%)                 0.839
  18.5--25.0                                         23 (54.7%)              124 (51.9%)               
  \>25.0                                             17 (40.5%)              98 (41.0%)                
  Number of comorbid diseases                                                                          
  0                                                  23 (54.8%)              101 (42.3%)               0.265
  1                                                  10 (23.8%)              84 (35.1%)                
  ≥2                                                 9 (21.4%)               54 (22.6%)                
  Location of primary cancer                                                                           
  Left                                               20 (47.6%)              152 (63.6%)               0.059
  Right                                              22 (52.4%)              87 (36.4%)                0.059
  Pre-operative carcinoembryonic antigen (CEA)                                                         
  \<5 ng/mL                                          27 (64.3%)              151 (63.4%)               1.000
  \>5 ng/mL                                          15 (35.7%)              87 (36.6%)                
  Bowel obstruction or perforation                                                                     
  No                                                 32 (76.2%)              215 (90.0%)               0.019
  Yes                                                10 (23.8%)              24 (10.0%)                
  Adjuvant chemotherapy                                                                                
  No                                                 11 (76.2%)              50 (20.9%)                0.424
  Yes                                                31 (73.8%)              189 (79.1%)               
  Stage (tumor/node/metastasis, TNM)                                                                   
  II                                                 15 (35.7%)              117 (49.0%)               0.132
  III                                                27 (64.3%)              122 (51.0%)               
  pT stage                                                                                             
  2                                                  1 (2.4%)                10 (4.2%)                 0.097
  3                                                  30 (71.4%)              197 (82.4%)               
  4                                                  11 (26.2%)              32 (13.4%)                
  pN stage                                                                                             0.076
  0                                                  15 (35.7%)              118 (49.4%)               
  1                                                  18 (42.9%)              62 (25.9%)                
  2                                                  9 (21.4%)               59 (24.7%)                
  Differentiation                                                                                      0.319
  Well                                               1 (2.4%)                6 (2.5%)                  
  Moderate                                           36 (87.8%)              223 (93.3%)               
  Poor                                               4 (9.8%)                10 (4.2%)                 
  Perineural invasion                                                                                  0.083
  No                                                 21 (50.0%)              155 (64.9%)               
  Yes                                                21 (50.0%)              84 (35.1%)                
  Venous invasion                                                                                      0.503
  No                                                 37 (88.1%)              199 (83.3%)               
  Yes                                                5 (11.9%)               40 (16.7%)                
  Lymphatic invasion                                                                                   0.610
  No                                                 27 (64.3%)              141 (59.0%)               
  Yes                                                15 (35.7%)              98 (41.0%)                
  Number of harvested lymoh nodes                    23.5 (10--63)           22 (4--115)               0.259
  Number of metastatic lymph nodes                   1 (0--15)               1 (0--18)                 0.560
  Metastatic lymphnodes/harvested lymph nodesratio   4.9 (0--66.7)           2.6 (0--100)              0.943
  *KRAS* ^1^                                                                                           0.811
  Wild-type                                          14 (66.7%)              77 (63.1%)                
  Mutant                                             7 (33.3%)               45 (36.9%)                

^1^*KRAS*; V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog gene.

jcm-08-01903-t002_Table 2

###### 

Cox regression analysis of overall survival for 281 patients with curatively-resected colon cancer.

                                                                   Crude Hazard Ratio (95% CI)   *p*-Value   Adjusted Hazard Ratio (95% CI)   *p*-Value
  ---------------------------------------------------------------- ----------------------------- ----------- -------------------------------- -----------
  Age ≥ 65 (years)                                                 5.08 (2.468--10.462)          \<0.001     5.93 (2.810--12.493)             \<0.001
  Male                                                             1.31 (0.738--2.316)           0.358                                        
  BMI (reference: \<18.5 kg/m^2^)                                                                                                             
  18.5--25.0 (kg/m^2^)                                             1.17 (0.355--3.853)           0.796                                        
  \>25.0 (kg/m^2^)                                                 0.98 (0.290--3.330)           0.978                                        
  Number of comorbid diseases (reference: 0)                                                                                                  
  1                                                                1.02 (0.520--1.985)           0.964                                        
  ≥2                                                               1.02 (0.776--2.963)           0.223                                        
  Right-sided location of primary cancer                           1.45 (0.827--2.527)           0.196                                        
  Pre-operative CEA ≥ 5 ng/mL                                      1.794 (1.030--3.126)          0.039       1.76 (1.008--3.027)              0.058
  Combined bowel obstruction or perforation at initial diagnosis   1.286 (0.578--2.859)          0.537                                        
  Adjuvant chemotherapy                                            2.240 (1.247--4.024)          0.007                                        0.034
  Stage III                                                        1.509 (0.852--2.672)          0.158                                        
  Differentiation (reference: well)                                                                                                           
  Moderate                                                         0.508 (0.123--2.096)          0.349                                        
  Poor                                                             0.531 (0.075--3.773)          0.527                                        
  Perineural invasion                                              1.443 (0.827--2.516)          0.197                                        
  Venous invasion                                                  1.545 (0.791--3.017)          0.203                                        
  Lymphatic invasion                                               1.542 (0.886--2.685)          0.120                                        
  Number of harvested lymph nodes                                  0.996 (0.792--1.021)          0.756                                        
  Number of metastatic lymph nodes                                 1.078 (1.004--1.156)          0.037       1.350 (0.718--2.539)             0.351
  *KRAS*^1^ mutated cancer                                         2.020 (0.779--5.236)          0.148                                        
  Low EEF1A1 expression                                            2.560 (1.380--4.749)          0.003       3.01 (1.636--5.543)              \<0.001

^1^*KRAS*; V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog gene.

jcm-08-01903-t003_Table 3

###### 

Cox regression analysis of disease-free survival for 281 patients with curatively-resected colon cancer.

                                                                   Crude Hazard Ratio (95% CI)   *p*-Value   Adjusted Hazard Ratio (95% CI)   *p*-Value
  ---------------------------------------------------------------- ----------------------------- ----------- -------------------------------- -----------
  Age ≥ 65 (years-old)                                             1.44 (0.852--2.442)           0.172                                        
  Male                                                             1.18 (0.697--2.008)           0.533                                        
  BMI (reference: \<18.5 kg/m^2^)                                                                0.651                                        
  18.5--25.0 (kg/m^2^)                                             0.69 (0.271--1.800)           0.457                                        
  \>25.0 (kg/m^2^)                                                 0.98 (0.290--3.330)           0.978                                        
  Number of comorbid diseases (reference: 0)                                                                                                  
  1                                                                1.04 (0.567--1.891)           0.909                                        
  ≥2                                                               1.15 (0.593--2.216)           0.685                                        
  Right-sided location of primary cancer                           1.24 (0.730--2.103)           0.428                                        
  Pre-operative CEA ≥ 5 ng/mL                                      2.35 (1.397--3.966)           0.001       2.23 (1.308--3.806)              0.003
  Combined bowel obstruction or perforation at initial diagnosis   0.88 (0.379--2.057)           0.773                                        
  Adjuvant chemotherapy                                            1.09 (0.578--2.066)           0.785                                        
  Stage III                                                        2.22 (1.256--3.908)           0.006       25.80 (3.087--215.562)           0.003
  Differentiation (reference: well)                                                              0.645                                        
  Moderate                                                         0.51 (0.123--2.096)           0.349                                        
  Poor                                                             0.53 (0.075--3.773)           0.527                                        
  Perineural invasion                                              1.34 (0.796--2.268)           0.268                                        
  Venous invasion                                                  1.19 (0.604--2.364)           0.610                                        
  Lymphatic invasion                                               1.52 (0.901--2.546)           0.117                                        
  Number of harvested lymph nodes                                  1.01 (1.002--1.026)           0.021       1.02 (0.994--1.042)              0.150
  Number of metastatic lymph nodes                                 1.10 (1.034--1.171)           0.003       0.24 (0.029--1.953)              0.182
  KRAS ^1^ mutated cancer                                          1.42 (0.665--3.036)           0.364                                        
  Low EEF1A1 expression                                            2.86 (1.619--5.042)           \<0.001     2.54 (1.459--4.434)              \<0.001

^1^*KRAS*; V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog gene.

[^1]: Eun kyo Joung and Jiyoung Kim contributed equally to this study.
